Description
Ropinprime (Ropinirole) 1 mg
Ropinprime 1 mg is a brand of ropinirole, a non-ergot dopamine agonist used in the treatment of Parkinson’s disease and, in some settings, restless legs syndrome. The product name and strength are used here for identification only.
Active Ingredient and Medicine Class
Ropinirole is a dopamine agonist that acts mainly at D2 and D3 dopamine receptors. It belongs to the non-ergoline antiparkinsonian medicines.
Established Medical Uses
Official prescribing information for ropinirole tablets identifies use in Parkinson’s disease and moderate-to-severe primary restless legs syndrome. In restless legs syndrome, published reviews and guidelines support symptom relief, although newer guidance notes that dopamine agonists are not preferred for routine long-term use because of augmentation risk.
How It Works
Ropinirole stimulates dopamine receptors in the brain, helping compensate for reduced dopaminergic signalling seen in Parkinson’s disease. In restless legs syndrome, dopaminergic activity is also thought to reduce the uncomfortable leg sensations and urge to move.
Important Safety Information
Ropinirole is not suitable for everyone. Regulatory labeling warns about somnolence or sudden sleep onset, syncope, orthostatic hypotension, hallucinations or psychotic-like behavior, and impulse control or compulsive behaviors. Caution is also advised with other sedating medicines, alcohol, and medicines that can raise ropinirole levels, such as ciprofloxacin.
Possible Side Effects
Common adverse effects reported in labeling include nausea, dizziness, sleepiness, syncope, vomiting, edema, and dyspepsia. In Parkinson’s disease, dyskinesia, confusion, hallucinations and orthostatic symptoms are also recognised. Serious reactions may include marked drowsiness, fainting, psychotic symptoms, and troublesome compulsive behaviors.
Scientific Evidence
Randomized and review evidence shows that ropinirole can reduce symptoms of restless legs syndrome and improve sleep-related outcomes compared with placebo. In Parkinson’s disease, dopamine agonist reviews describe ropinirole as an established symptomatic treatment, with adverse effects typical of the class. Recent sleep-medicine guidance still notes a benefit in RLS, but advises against standard routine use because of augmentation concerns over time.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA — ROPINIROLE tablet, film coated
- FDA — REQUIP (ropinirole) tablets, for oral use
- Bogan RK et al. “Ropinirole treatment for restless legs syndrome.” Expert Opinion on Pharmacotherapy (2008). PubMed